Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies - ACR Meeting Abstracts

Por um escritor misterioso
Last updated 23 dezembro 2024
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
Background/Purpose: Although the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to assess the activity of axial disease in patients (pts) with PsA, only one of its questions is specific to axial symptoms. Alternatively, the Ankylosing Spondylitis Disease Activity Score (ASDAS) excludes assessment of enthesitis, gives less weight to peripheral activity and is considered […]
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
PDF) Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies - The Lancet Rheumatology
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial, Trials
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
OP0054 EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis - ACR Meeting Abstracts
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
PDF) The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
Identification of PsA Phenotypes with Machine Learning Analytics Using Data from a Phase 3 Clinical Trial Program of Guselkumab in a Bio-naïve Population of Patients with PsA - ACR Meeting Abstracts
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
POS0934 EFFICACY OF UPADACITINIB ON PSORIATIC ARTHRITIS WITH AXIAL INVOLVEMENT DEFINED BY INVESTIGATOR ASSESSMENT AND PRO-BASED CRITERIA: RESULTS FROM TWO PHASE 3 STUDIES
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
PDF) Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
Treating to Target(s) With Interleukin-17 Inhibitors - Charles W. Lynde, Jennifer Beecker, Jan Dutz, Cathy Flanagan, Lyn C. Guenther, Wayne Gulliver, Kim Papp, Proton Rahman, Dalton Sholter, Gordon E. Searles, 2019
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
PDF) Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA

© 2014-2024 progresstn.com. All rights reserved.